Citation Impact
Citing Papers
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
2015 Standout
Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis
2023 StandoutNobel
A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C
2003 Standout
Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis
2009
Diagnosis and Epidemiology of Cirrhosis
2009
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004
2004
In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis
2011
Limitations of non-invasive tests for assessment of liver fibrosis
2020
Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease
2016
Current concepts and controversies in the treatment of alcoholic hepatitis
2006
Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis
2015
Liver fibrosis
2005 Standout
Sampling Variability of Liver Fibrosis in Chronic Hepatitis C
2003 Standout
The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
2008
Hepatic Expression of Candidate Genes in Patients With Alcoholic Hepatitis: Correlation With Disease Severity
2006
Noninvasive monitoring of patients with chronic hepatitis C
2002
Mechanisms of liver fibrosis
2005
A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France
2012
Acute Portal Vein Thrombosis Unrelated to Cirrhosis: A Prospective Multicenter Follow-Up Study
2009
Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors
2004
Biochemical Surrogate Markers of Liver Fibrosis and Activity in A Randomized Trial of Peginterferon Alfa–2B and Ribavirin
2003
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
2005 Standout
Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study
2005
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
2013 StandoutNature
Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study
2010
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
2017 Standout
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model
2002
Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in haemochromatosis
1999
Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries
2011 Standout
Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology
2000
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
2005
Interleukin-22 Treatment Ameliorates Alcoholic Liver Injury in a Murine Model of Chronic-Binge Ethanol Feeding: Role of Signal Transducer and Activator of Transcription 3
2010
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
2015 Standout
Acute-on chronic liver failure
2012
Natural history of hepatitis C
1997
Transformation-dependent susceptibility of rat hepatic stellate cells to apoptosis induced by soluble fas ligand
1998
Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients
2004
Hepatitis B virus infection
2009 Standout
Psoriasis
2021 Standout
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
2012
Clinical Magnetic Resonance Imaging of Pancreatic Islet Grafts After Iron Nanoparticle Labeling
2008
Down‐regulation of cyclin E1 expression by microrna‐195 accounts for interferon‐β‐induced inhibition of hepatic stellate cell proliferation
2010
Reversal of Fibrosis: No Longer a Pipe Dream?
2006
Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice
2011
Noninvasive diagnosis of the degree of hepatic fibrosis using ultrasonography in patients with chronic liver disease due to hepatitis C virus
2001
Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
2013 Standout
From NAFLD in clinical practice to answers from guidelines
2013
Pharmacological agents for NASH
2013
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Management of Hepatocellular Carcinoma *
2005 Standout
Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice
2003
Antithrombotic Therapy for VTE Disease
2012 Standout
Two to Tango: Regulation of Mammalian Iron Metabolism
2010 Standout
Biodistribution and function of extracellular miRNA-155 in mice
2015 StandoutNobel
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
2013
Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases
2007 Standout
Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension
2002
A role of PIEZO1 in iron metabolism in mice and humans
2021 StandoutNobel
Liver-Derived Hepatitis C Virus (HCV)-Specific CD4+ T Cells Recognize Multiple HCV Epitopes and Produce Interferon Gamma
2000 StandoutNobel
Non-alcoholic fatty liver disease
2021 Standout
A comparison of fibrosis progression in chronic liver diseases
2003
A Ribosomopathy Reveals Decoding Defective Ribosomes Driving Human Dysmorphism
2017 StandoutNobel
Up-regulation of MicroRNA-155 in Macrophages Contributes to Increased Tumor Necrosis Factor α (TNFα) Production via Increased mRNA Half-life in Alcoholic Liver Disease
2010
Mechanisms of Hepatic Fibrogenesis
2008 Standout
Chronic hepatitis B
2007 Standout
Haemochromatosis
2018
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Transient Elastography for the Noninvasive Assessment of Liver Fibrosis: A Multicentre Canadian Study
2010
Sickle-cell disease
2010 Standout
Development and validation of a model to diagnose cirrhosis in patients with hepatitis C
2002
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis
2018
Effect of Etanercept Plus Lamivudine in a Patient With Rheumatoid Arthritis and Viral Hepatitis B
2008
PPARγ signaling and metabolism: the good, the bad and the future
2013 Standout
Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids
2007
Severe sepsis in cirrhosis†
2009
Prominent contribution of portal mesenchymal cells to liver fibrosis in ischemic and obstructive cholestatic injuries
2007
Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis
2013 Standout
Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference
2008
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
2012
Expression of subtypes of somatostatin receptors in hepatic stellate cells
2004
Advances in functional and molecular MRI technologies in chronic liver diseases
2020
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids
2007
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis
2010
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
2011 Standout
Serum markers detect the presence of liver fibrosis: A cohort study
2004
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
2006 Standout
Translating an Understanding of the Pathogenesis of Hepatic Fibrosis to Novel Therapies
2013
Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey
2000
Somatostatin inhibits pro‐inflammatory cytokine secretion from rat hepatic stellate cells
2005
Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: A longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline
2005
A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease
2010
A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Etanercept in the Treatment of Alcoholic Hepatitis
2008
Estrogen reduces CCL4- induced liver fibrosis in rats
2002
Infection in Patients With Severe Alcoholic Hepatitis Treated With Steroids: Early Response to Therapy Is the Key Factor
2009
Liver Biopsy
2001 Standout
Alcoholic Liver Disease
2009
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C
2003
Hepatocellular carcinoma
2022 Standout
Alcoholic steatohepatitis
2010
HEPATIC FIBROSIS
2001
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study
2001
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Evaluation of Liver Fibrosis: A Concise Review
2004
R2* magnetic resonance imaging of the liver in patients with iron overload
2009
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals
2013
Progression of fibrosis in advanced chronic hepatitis C
2007
Interferon Alfa Down–Regulates Collagen Gene Transcription and Suppresses Experimental Hepatic Fibrosis in Mice
2003
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Diagnosing Fibrosis in Hepatitis C: Is the Pendulum Swinging From Biopsy to Blood Tests?
2003
Pharmacotherapy for Nonalcoholic Fatty Liver Disease
2015
Alcoholic Hepatitis
2009
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
2007 Standout
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Noninvasive monitoring of patients with chronic hepatitis C
2002
Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers
2019
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis.
2006
Genetic and Functional Characterization of the N-Terminal Region of the Hepatitis C Virus NS2 Protein
2013 StandoutNobel
Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders
2005
Nonalcoholic Fatty Liver Disease
2015 Standout
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
Works of F. Oberti being referenced
Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study
2006
Fractal dimension can distinguish models and pharmacologic changes in liver fibrosis in rats
2002
Prothrombin index is an indirect marker of severe liver fibrosis
2002
Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C
2008
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
2010
Criteria to Determine Reliability of Noninvasive Assessment of Liver Fibrosis With Virtual Touch Quantification
2018
Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores
1998
Effects of long-term administration of interferon α in two models of liver fibrosis in rats
1998
Antifibrotic and Hemodynamic Effects of the Early and Chronic Administration of Octreotide in Two Models of Liver Fibrosis in Rats
1998
Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography
2008
Respective roles of porto‐septal fibrosis and centrilobular fibrosis in alcoholic liver disease
2003
Noninvasive diagnosis of hepatic fibrosis or cirrhosis
1997
Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis
1999
Non-invasive assessment of hepatic iron stores by MRI
2004
A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis
2004
47 A MULTICENTRIC, DOUBLE-BLIND, RANDOMISED- CONTROLLED TRIAL (RCT) OF HIGH DOSE URSODEOXYCHOLIC ACID IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)
2009
1043 PENTOXIFYLLINE (PTX) REDUCES THE RISK OF COMPLICATIONS IN PATIENTS WITH ADVANCED CIRRHOSIS. ANALYSIS OF THE RESULTS OF A PIVOTAL PHASE 3 TRIAL
2009